Artiva Halts AlloNK Development, Lays Off 94% of Staff After Patient Deaths and Durability Shortfalls

Artiva Biotherapeutics stops development of its autoimmune NK cell therapy AlloNK and cuts 94% of staff after two patient deaths and poor durability data.